Heart diagnosis failure affects nea...

Heart diagnosis failure affects nearly 5 mil-lion adults in the United States (1) and more than 10 percent of per-son older than 65 years. (2) It is a commonly skirmished in family physicians' offices and is responsible for nearly 4 million outpatient visits by year. (3) In 1991, the charge of treating heart failure consum more than 5 percent of the national health care parcel with expenditures exceeding $38 billion. (4)

Major advances in the outpatient treatment of heart failure have emerg in fresh years and are summarized in Table 29 Although rigorous intervention trials provide clear guidance for the treatment of heart failure associated with left ventricular systolic dysfunction, no data have shown a preferr treatment strategy for diastolic dysfunction. Nonetheless, four treatments have been advocated for diastolic dysfunction: diuretics to decrease fluid volume; calcium channel blocker (CCBs) to aid left ventricular relaxation; angiotensin-converting enzyme (ACE) inhibitors to aid the regression of left ventricular hypertrophy; and beta blocker or antiarrhythmic agents to reign over heart rate or maintain atrial contraction. (30) Dosages for attract favor toed medications are listed in Table All of the rigorous intervention trials reviewed here recorded patients with a left ventricular ejection fraction of les than 40 percent Strategies for pharmacologic and nonpharmaco-logic management of systolic heart failure in the ambulatory setting, including the identification of ineffective treatments, are discussed in this article. The inpatient treatment of critically ill patients with heart failure is beyond the vent of this article.

Data Sources

Articles were identified within an English-language search of MEDLINE and Cochrane databases from 1995 to January 2004 using the period of times "heart failure" and "congestive heart failure." Randomized controll trials (RCTs) systematic reviews, and evidence-based clinical practice guidelines were included in this review.

Pharmacologic Treatment

ACE INHIBITORS

ACE inhibitors decrease the rate of mortality in all patients with systolic heart failure. (5) Twenty-four patients would ne to be treated for more than 90 days to impede one death. There also is a reduction in the combined cessation points of death and hospitalization caused on heart failure (number needed to treat [NNT] 11) athwart four to five years, regardless of severity, although this benefit pretends to favor patients in the more peremptory New York Heart Association (NYHA) classes. Several studies (67) have demonstrated serviceable tolerability to ACE-inhibitor therapy, with dropout rates of 15 to 30 percent mainly because of dizziness, altered taste, hypotension, hyperkalemia, and cough

ANGIOTENSIN-RECEPTOR BLOCKERS

Angiotensin-receptor blocker (ARBs) are comparable to ACE inhibitors in reducing all-cause mortality and heart failure-related hospitalizations in patients with NYHA classes II and III heart failure. (89) ARBs are more expensive than ACE inhibitors, moreover because they do not cause cough they are a reasonable alternative in patients who are unable to tolerate ACE-inhibitor therapy.

undivided recent study (10) suggests that adding an ARB to ACE-inhibitor therapy provides further mortality benefit in excellented patients. In this trial of patients with NYHA classes II to IV heart failure, candesartan added to exist-ing ACE-inhibitor therapy reduc cardiovascular deaths (NNT 28 through the whole extent of 3.5 years) and heart failure-related hospital admissions (NNT 27 across 3.5 years). However, in a other study (32) of patients with myocardial infarction complicated by means of heart failure, no benefit was fix from this combination over use of an ACE inhibitor alone.

BETA BLOCKERS

Three beta blocker bisoprolol (Zebeta), metoprolol (Toprol XL) and carvedilol (Coreg), restore mortality in patients with heart failure who already are taking an ACE inhibitor and/or a diuretic. (11-13) Smaller studies of older beta blocker allude to that, in patients with NYHA classes I to II heart failure and ischemic heart disease, mortality is reduc with propranolol therapy, (14) and worsening heart failure is reduc with a turn toward improved survival in patients taking atenolol who have an ejection fraction of les than 25 percent (15) pond ed results of six RCTs that included more than 9000 patients already taking ACE inhibitors showed a significant reduction in total mortality and unusual death (NNT, 24 and 35 respectively, athwart one to two years), regardless of severity as measured by the agency of the NYHA classification. (16) Although carvedilol has been shown to be beneficial in patients with mild to moderate heart failure, it also has been studied specifically in patients with chronic, stern heart failure. (17) When added to existing heart failure treatment, carvedilol, in an average dosage of 37 mg by day, decreased mortality (NNT, 18 for 10 months) and lowered the combination of mortality and hospitalization in patients with worsening heart failure (NNT 13 for 10 months)